Adocia announced the launch of two new projects employing its proprietary BioChaperone® technology: the combination of insulin lispro with pramlintide (amylin analogue, Symlin®, AstraZeneca) and the combination of insulin lispro with exenatide (GLP-1 receptor agonist, Byetta®, AstraZeneca). Insulin is a life-saving therapy for people with type 1 diabetes. However, even optimally controlled patients using insulin exhibit profound glycemic variability and frequently fail to reach their treatment goals. This may be partly because, in people without diabetes, insulin, amylin and GLP-1 are secreted in synchrony and act in synergy to control blood glucose. In type 1 diabetes, ultimately, neither insulin nor amylin is secreted and GLP-1 secretion is deficient. Both pramlintide, a short-acting amylin analog, and exenatide, a short-acting GLP-1 receptor agonist, have been approved for the treatment of type 1 and type 2 diabetes, respectively. It has been demonstrated in clinical trials that, when added to an existing insulin regimen, these molecules improve HbA1c and reduce prandial insulin consumption, weight gain, and side effects. However, insulin therapy for people with type 1 diabetes requires intense patient involvement, including multiple daily injections and frequent glucose monitoring. To maintain patient persistency, new treatment options in diabetes should not only demonstrate superior efficacy, but also avoid increasing the everyday burden of disease management, while remaining affordable. This formulation strategy, based on real-world clinical data with the separate hormones, could shorten development time. The BioChaperone projects also have the potential to support competitive pricing by leveraging approved, off-patent proteins.